|
|
| Home | Speakers | Programme | Venue | Delegates | Sponsors | Media | Register |
  |
Sponsors Gold Sponsor  Established in 2008, Choice Pharma currently has 9 offices across 6 countries in Asia – an operational network that provides optimal support for clinical programs throughout the region. Alongside our qualified and experienced project managers, medical monitors and CRAs, the Choice Pharma team also includes pharmaceutical industry specialists and former regulators who work closely with regional and national authorities. This breadth of experience gives Choice Pharma a comprehensive understanding not simply of clinical trial management, but of international clinical development in its wider context. On a regional basis, our management team provides the strategic vision required to plan and implement multi-national clinical projects while our regulatory strategy services are of particular value to clients less familiar with Asia-Pacific markets. Across our Asia-Pacific office network, our specialist teams draw on the invaluable working relationships they have built with key clinical investigators and study sites throughout the region. They also have a native familiarity with local cultures and languages which is vital in ensuring effective communication. Quality and reliability are critical to everything we do and to this end a commitment to training and development runs throughout the organisation. From site selection and patient recruitment, through project management to data monitoring and analysis, our entire business model is built around rigorous adherence to the principles of good clinical practice. Choice Pharma has extensive clinical experience, from first-into-human evaluations through phase IV studies, and covers virtually every key therapeutic area. Sliver Sponsor  PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates over 70 locations throughout more than 50 countries around the world, and has over 11,000 employees. PAREXEL strives to be the premier provider to the biopharmaceutical and medical device industries for development and commercialization of new medical therapies worldwide. PAREXEL’s mission is to combine the strength of our expertise, experience and innovation to advance the worldwide success of the bio/pharmaceutical and medical device industries in preventing and curing disease. For more information about PAREXEL International visit www.PAREXEL.com. Bronze Sponsors  Quick facts
 LSK Global PS is a full service Korean CRO and has been in business since March 2000, one of the oldest CROs in Korea. LSK has been growing steadily and its technical expertise reaches the global standard. Since its establishment, LSK has completed or is engaged in near sixty multinational studies, and has prepared or made over 40 Korea FDA IND submissions. Korea is attracting multinational clinical trials and on its way to become the hub for multinational drug development in Northeast Asia. There are a number of reasons. Korean regulatory process is one of the best streamlined in Asia. Korean medical infrastructure is as advanced as in western nations. Most Korean investigators, if not all, have post-medical training in the US and are familiar with clinical trials. It is generally known the higher the level of education the higher the quality of clinical trial data. Korea has one of countries with the highest level of education in the world. Korea is known for timely recruitment of study subjects. Political and economic stability is another important factor. China, Japan, and Korea are close to each other in genetic polymorphism and disease profiles. Recently, Japan has decided to accept clinical trial data from Korea for its drug approval. This policy decision positions Korea as an important country for Japanese drug development. Local expertise is important for study start-up as the SSU process in Korea can be substantially different although end products are the same. LSK excels in this. LSK is also strong in data management and statistics, meeting the global standard. LSK can produce data meeting the requirement of US FDA and EU EMA at a much more reasonable price. We will be happy to provide you whatever information you may need to assess your future strategy in Asia and Korea. Sponsored by Seoul Metropolitan Government  Exhibitors
 The
establishment of the Alliance for Pacific Asia
Clinical Trials (A-PACT) marks the beginning of a
new era in Pacific Asia (PA) Regional study
outsourcing. Through unified service capabilities
and experience among some of the best local CROs in
the key clinical trial areas in PA, we are able to
provide you with a one-stop solution to your PA
Regional study needs. We can provide you with global
management of your clinical studies, as well as
consulting services for market and RA feasibility in
the PA region, at global quality standards and at a
more competitive, local price.
The four founding members include ACM of Japan, C&R Research of South Korea, Rundo International of Mainland China and VCRO of Taiwan, each with a proven track record and strong local market position - it was upon this foundation that A-PACT was established.  A Plus Inc. is
an Asia regional Contract Research Organization
(CRO) and its parent company, PPC (Protech
Pharmaservices Corporation) was established in 1997
with headquarters in Taiwan, with more than 13 years
of experience.
A Plus Inc. offers full service to human clinical trials (Phase I to IV), has conducted around 300 clinical trials so far, with emphasis on multi-national project management and local execution expertise. A Plus Inc. is one of the major providers of clinical trial services in the Asian countries and is also the first oversea company that has successfully passed the inspection by Japanese Pharmaceutical and Medical Devices Agency (PMDA) in 2010 for operating a multi-national study in Asia countries. In 2011, A Plus Inc., the clinical service section of PPC, has spin off from PPC Group and become an independent company, which is still 100% owned by PPC. A Plus Inc. aims to fulfill the needs of clients by delivering the highest quality and value with a keen focus on time and cost-effectiveness of clinical trials. PPC Group manages satellite operation units in Taiwan, China, Japan, Korea, Hong Kong and Singapore. PPC establishment is firmly rooted in Asia with more than 250 employees to offer optimized solutions for every clinical trial. PPC's Central Laboratory is a fully CAP/CLIA accredited clinical laboratory – first Central Lab in Taiwan to gain CAP accreditation since 2002.  Medidata
Solutions is a leading global provider of SaaS
clinical development solutions that enhance the
efficiency of customers’ clinical trials. Medidata’s
advanced solutions lower the total cost of clinical
development by optimizing clinical trials from
concept to conclusion: from study and protocol
design, trial planning and budgeting, site
negotiation, clinical portal, trial management,
randomization and trial supply management, clinical
data capture and management, safety events capture,
medical coding to business analytics.
Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.  Who we are….George
Clinical is an Academic Research Organisation (ARO)
established by The George Institute for Global
Health to design and manage large-scale clinical
trials both for the Institute and for pharmaceutical
and medical research organisations worldwide.
What we do….As an ARO, George Clinical couples the medical and scientific expertise of the George Institute with operational excellence and a broad Asia Pacific presence to conduct influential and cost effective large scale clinical trials. Asia Pacific presence with global reach….George Clinical has staff and facilities in Australia, Hong Kong, Singapore, Malaysia, India and China and has established partnerships with other leading Academic Research Organisations in North America, Europe and Asia. In this way George Clinical provides a comprehensive service with global reach. Current clients of George Clinical include major pharmaceutical companies. Our Competitive Advantage….Our competitive advantage is derived from the combination of global reputation, scientific expertise and operational excellence. Our academic leadership allows us to engage with investigator sites and key opinion leaders in an independent and credible fashion which translates to optimal patient recruitment and effective study delivery. Operational experience….George Clinical study experience spans a number of therapeutic areas key ones being cardiovascular disease & diabetes, renal disease and neurology. Our sponsorship packages offer a wide range of attendance options to suit your budget and as well as exhibiting and taking part in prearranged one to one meetings can also incorporate pre-event marketing, branding and speaker presentations on the main conference agenda.  Integrated Solutions from Research to Commercialisation. Almac is a financially secure, privately owned organization with over 3,300 employees located within the US and UK. 600+ companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years. Our vast range of services include: Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA lab. API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides. Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply. Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes. Clinical Trial Supply: Offering over 20 years’ experience in clinical supply, packaging, distribution and management. Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials. Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution. Almac – Partnering to Advance Human Health™  ADM Korean Inc. is a company to provide full clinical service to sponsors. Each initial of ADM represents as like; “A” means “Asia” and “No.1`”, “D” means “Drug” and “Development” and “M” means “Man power” and ”Management” which are the most important factors as a CRO. So, the name of ADM expresses the vision of the company, “No.1 clinical service provider in Asia with the best people”. In order to realize this vision, we are doing our best in each project to get the best quality, efficiency and clinical results. Our distinguishable strong points are; 1. Man power : Experienced and well trained PM, CRM, CRA 2. Reputation : Good relationship with key investigators, KFDA reviews and sponsors 3. Stability : Good management for CRA 4. Smooth Communication with Clients : Customized Service 5. Punctuality on Project : System & Quality By meeting global standards and using local advantages, we`ll provide best solutions for clients. To keep good quality of our services, all employees comply with our Standard Operating Procedures and Quality Assurance department regularly audits all departments. Korea is the best region among the Asian countries in terms of clinical study. A lot of globally famous and active principal investigators, experienced investigators, highly compliant patient pool and reasonable government officers are waiting for your project in Korea. More than 150 huge general hospitals having a lot of experiences of multi-national clinical studies exist in Korea. All related guidelines in Korea are already harmonized with ICH`s one. In addition, Koreans are famous as hard workers. These factors make Korea “Asian Hub in clinical research area”. In fact, during recent three years, Korean FDA has approved above 100 INDs for multinational studies every year. There are about 10 clinical service providers in Korea. ADM Inc. is one of them to provide full clinical service to sponsors. How to select your Korean partner among them? The answer is very clear. Contact us. Visit us. You will find the difference clear between us and other CROs located in Korea. “Very
good. The prearranged nature of the meetings
was excellent”
President, i3 Research “The meetings you provided were brilliant. This was an excellent way to discuss business. I have several leads and an excellent opportunity has presented itself. Thank you once again, and I thoroughly recommend Global Engage's events” Eric Hilton, Business Development Director Food & Drug Analytical Services Ltd. For further
details please contact Steve Hambrook
(Conference Director).
Telephone +44 (0) 7949400917 or email steve@globalengage.co.uk |
 In association with:  |
|
Copyright: Global Engage Ltd.
Registered in England. No: 6950636 |